summary the the volumes results of the of a and covered Thanks, top trends just slide on Solomon. set here Steve the The is at quarter. major for call. revenues
signing the dynamic of revenue revenue very exactly we year-on-year growth XXXX a see to a hoped can actually that comparison. revenue headwind for deals the recognition medicine and what two rows first You BGI foundation the growth had was chart and robust and see. the by That's the was in healthy driven accounting-driven growth around product revenue on
for to of microdeletions as stable Panorama part to consistent the testing Horizon Within carrier with was mix in reproductive seen COGS continued about improve. between the per which the Panorama continue unit health is NIPT we've the of screening a five health XX% and time, we see business the what business, or last more. years ordered and women's
over the are to several but when $XXX really history On the driven clear, price. get I coverage quarters category benefit benefit the think gradually as average-risk in will per improving changes, we NIPT NIPT accounting P&L more payor saw trends We from on be started now NIPT below we we full accruals paid ASP, To away translate the required policies. is to we average in policies, revenue visible selling for unit revenue. and that coverage with getting right impact coverage changing but by the history on started
gross So unit to to improve. owing continue in businesses I'll our were a softer on our slightly fairly the impact reproductive That's reimbursed. health transient discuss the as guide. economics driving also to new margins prior fully for tests volumes getting some Overall
of data we exomes like research. doing behind is the side, targeted making include the crucial effort On not a story for this are leadership, accelerate out two develop a infrastructure win published to the but on and build-out technology to collecting work we the commercialization expenses same the committed and These this can for kind the R&D minority provide Panorama dimension R&D. cancer AI much we also R&D were technology always team going. oncology. on able our from in There's and leveraging and the just early-stage to have very the efforts It's the in addressable of of results significantly physician new is sure of to Signatera our really Accelerating experience every Prospera categories tests that market. are in our of things One franchises. the expand and patient. teams we We've can we true build
The risk requires relatively second effort the on are from much of and people, the focused but a development really returns low work is high-quality that very clear. larger effort technical lot is time and
could you reviews in our us sit all of you want of these to fund them. If would projects
our are paid to in have set with us indications. off large of academia this growing area. to is more projects aggressive projects of competitive generate partnering to the use studies strong advantage. category effort and year last data We for this in built These sample validation we One types our of and in the obviously and past banks able we've a a run to have in oncology happy it cash to been position
favorable vendors those and example $XX QX. in partners return for than For million our and we of long-term prepayments prepayments made roughly previous guide. year burn in below cash more Other actually our from deals, in came terms last
Okay.
Let's the call. for and at get headline to you of the top the next guidance gave XXXX. the Steve the the year slide
$XXX page. $XXX to $XXX million cash margins expect our We you revenues range expecting to the be XX% across distributed to year million, and this gross $XXX burn in SG&A be on the and are we XX% to million to million as R&D see can
lines. key of walk the assumptions for these Let's of each through each
see revenue given mature. the reproductive across sales all line that business In per to we presumes areas. health, we've growth historically unit will three that absolute volume team volume on more strong rep continue the First, growth is focused
up less that adoption The these NIPT large also very which big a recognizing and now point to take control. that average are think a recent markets them. our in unit a don't to have our gross ASP forecasting We with The require up the mainly, conservative very a for the the being sold a market behind up have So selling year. you huge can just cost good against trends, modeling improve, not of coverage, for reproductive transplant direct course presume also the balanced diagnostics the trajectory unit QX NIPT given We've businesses will the philosophical per in guide presumes on in far of units end But basically average-risk running move and the history goods margin also assumptions we and because last because That's we year's several great tack teams in in for broader ASPs Similarly opening of but continues But the time to does get oncology seen so decline. about margin specific conservative feel have that, we wise are as a from for just NIPT trajectory volume tried largely had. we've we going health these the we pace under timing are factors since assumption improving areas. execution growth gross could we the hold if this because it's year. guide. to assumptions we've your because slightly speed blended approach categories of year in control. guide price year assume – similar the just new both are taken of short of can windfall crosscurrents produce period not
For better example, down cutting platform and Pano our rates again. the AI supply once got on agreement is redraw Illumina we've a
trends are in should which We both growth pleased much unit the are on volume technology. with cost core on be as based our as also to transplant, no margins more mentioned. surprise in The I is franchises since per and are transient we seeing linked pressure oncology gross
out half decision the QX my have I the second from on grow IO in For results. I hope major we quickly, expect the reimbursement basically but don't of XXXX more and one are on the example, point. lines indication until to R&D the those and excited about covered year SG&A stay that for obscured the variable half do of units CMS of increases there's we flat and in QX based of QX, mapped year. in page. I think gets monitoring drivers the at a launching objectives final to and the this the review expect second in grow
and relatively picking the as reproductive space the That's especially much capital-efficient volume try health confident for profit price additional We the product more flow the per our than the in flow of focused talked primarily We we've M&A see confidence technologies in and would here strong. is and in and some targeting health markets huge front, that the to unit the done Even feel past us engine that's for our SG&A targets cash for oncology. stay think at investing and We'll really test, growth organic can the but call. be these dollars are about year business. you'll opportunistic we on small I mentioned gross the breakeven to breakeven built because we investments have in to should effective growth up line need seen, in on milestone of Many us, reproductive the activities, top and Steve is relevant transplant are selectively cross doing pay making investment in a the in to players full found and features is, acquisitions. what R&D team. to lots we've metrics we've commercial with that and we of large this new get give we cash over some the instead support
XXXX. excited are summarize, we to So about very
to unlock are far We progresses. we in off so year to catalysts the a great a got start interesting QX think as bunch we've and of
So with that, let the questions. Operator? for hand operator me to back it
